Compare Regeneron Pharmaceuticals Inc (REGN) vs Wells Fargo & Co (WFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Wells Fargo & Co — how do they compare? Regeneron Pharmaceuticals Inc trades at $745.31 (market cap $76.14B), while Wells Fargo & Co trades at $82.65 (market cap $248.06B). The key difference: Wells Fargo & Co is far larger — about 3.3× Regeneron Pharmaceuticals Inc's market cap, and Wells Fargo & Co pays the higher dividend (2.44%). Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Wells Fargo & Co for 87 Days on average.
| REGN | WFC | |
|---|---|---|
Market Cap | $76.14B | $248.06B |
Volume | 500,239 | 16,615,741 |
Sector | Health | Financials |
52-Week High | $852.03 | $96.40 |
52-Week Low | $557.73 | $73.42 |
Typical Hold Time | 107 Days | 87 Days |
Enterprise Value | $70.85B | $503.91B |
Dividend Yield | 0.51% | 2.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
Wells Fargo (WFC) trades at $80.26, down 1.53% today, with a bearish technical signal despite recent earnings beat in Q2 2026. The company shows strong fundamentals with a P/E of 11.92, net income margin of 25.97%, and a recent credit rating upgrade to 'A-' by S&P (Zacks Investment Research, 2026-10-01). Revenue growth is steady, reaching $83.70B in 2025, with a consensus price target of $99.13 suggesting upside potential.
The stock presents a value opportunity with attractive valuation metrics and improving profitability, but faces risks from volatile cash flows and regulatory changes in bank stress tests. Analyst sentiment is mixed with 46.66% buy ratings, while technical indicators signal near-term caution. Upside hinges on Q3 2026 earnings meeting expectations of $1.85 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Wells Fargo & Co
Wells Fargo is one of the largest banks in the United States, with approximately $1.9 trillion in balance sheet assets. The company is split into four primary segments: consumer banking, commercial banking, corporate and investment banking, and wealth and investment management. It is almost entirely focused on the U.S.
Read more on WFC →
